Period:
Draw Mode:
| Volume | 127,083 |
|
|||||
| News | - | ||||||
| Day High | 50.105 | Low High |
|||||
| Day Low | 48.67 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Sage Therapeutics Inc | SAGE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.055 | 0.11% | 49.555 | 15:07:13 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 49.36 | 48.67 | 50.105 | 49.50 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,742 | 127,083 | $ 49.53 | $ 6,294,836 | - | 30.665 - 54.86 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:07:19 | 3 | $ 49.54 | USD |
Sage Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 2.96B | 59.76M | 51.28M | $ 3.29M | $ -1.47M | -2.46 | -2,017.19 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 11.22k | 0.30% |
Sage Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SAGE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 51.37 | 51.1499 | 48.89 | 49.57 | 412,443 | -1.82 | -3.53% |
| 1 Month | 47.34 | 54.86 | 46.0375 | 51.25 | 465,592 | 2.22 | 4.68% |
| 3 Months | 44.82 | 54.86 | 38.665 | 46.27 | 523,481 | 4.74 | 10.56% |
| 6 Months | 40.92 | 54.86 | 36.91 | 44.19 | 507,304 | 8.64 | 21.1% |
| 1 Year | 31.63 | 54.86 | 30.665 | 40.09 | 556,163 | 17.93 | 56.67% |
| 3 Years | 35.61 | 98.385 | 27.36 | 49.71 | 615,072 | 13.95 | 39.16% |
| 5 Years | 154.33 | 193.56 | 25.01 | 70.87 | 637,180 | -104.78 | -67.89% |
Sage Therapeutics Description
| Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. |